D-Pro9-Cetrorelix incorporates a D-proline substitution that introduces pronounced conformational restriction at position 9. The change influences backbone curvature, proteolytic resistance, and receptor-contact geometry. Researchers examine its altered binding patterns relative to native cetrorelix. Applications include SAR exploration, peptide stabilization strategies, and structural-biology research.
CAT No: Z10-101-210
Synonyms/Alias:(R)-1-(((R)-2-((S)-2-((S)-2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanamido)-3-hydroxypropanamido)-3-(4-hydroxyphenyl)propanamido)-5-ureidopentanoyl)-L-leucyl-L-arginyl)-N-((R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide; Ac-D-2-Nal-D-Phe (4-Cl)-D-3-Pal-Ser-Tyr-D-Cit-Leu-Arg-D-Pro-D-Ala-NH2;(R)-N-((R)-1-amino-1-oxopropan-2-yl)-1-((2S,5R,8S,11S,14R,17R,20R)-3-((S)-2-amino-4-methylpentanoyl)-17-(4-chlorobenzyl)-2-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-(hydroxymethyl)-20-(naphthalen-2-ylmethyl)-4,7,10,13,16,19,22-heptaoxo-14-(pyridin-3-ylmethyl)-5-(3-ureidopropyl)-3,6,9,12,15,18,21-heptaazatricosan-1-oyl)pyrrolidine-2-carboxamide
D-Pro9-Cetrorelix is a synthetic decapeptide analogue engineered to function as a potent gonadotropin-releasing hormone (GnRH) antagonist. Distinguished by the substitution of D-proline at position nine, this peptide demonstrates enhanced metabolic stability and resistance to enzymatic degradation, making it a valuable tool in biochemical and molecular research. Its unique structure allows it to bind competitively to GnRH receptors, thereby modulating the secretion of key pituitary hormones. Due to its precise mechanism of action and favorable pharmacological profile, D-Pro9-Cetrorelix has become integral to a wide range of experimental applications across reproductive biology, endocrinology, and pharmaceutical development. Researchers appreciate its utility in both in vitro and in vivo settings, where it can be reliably employed to dissect hormone signaling pathways and investigate receptor-ligand interactions.
Reproductive Biology Research: D-Pro9-Cetrorelix is extensively utilized in reproductive biology investigations to elucidate the regulatory mechanisms of gonadotropin secretion. By acting as a competitive antagonist at the GnRH receptor, it enables researchers to effectively suppress the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from pituitary cells in culture or animal models. This targeted inhibition facilitates the study of feedback loops within the hypothalamic-pituitary-gonadal axis and provides insights into the hormonal control of reproductive processes. The peptide's stability and specificity make it ideal for dissecting the temporal dynamics of hormone release and for mapping downstream signaling events triggered by GnRH blockade.
Endocrine Signaling Studies: In the context of endocrine research, D-Pro9-Cetrorelix serves as a powerful tool for probing the physiological and molecular consequences of GnRH receptor inhibition. Scientists employ it to investigate the broader impact of disrupted GnRH signaling on endocrine homeostasis, including alterations in gonadal steroidogenesis and secondary hormonal cascades. Its use in cell-based assays and animal experiments allows for the controlled modulation of hormone levels, enabling detailed analysis of compensatory mechanisms and cross-talk between different endocrine pathways. As a result, it contributes significantly to advancing our understanding of hormonal regulation and dysfunction within complex biological systems.
Pharmaceutical Development: The peptide analogue is frequently incorporated into drug discovery programs focused on identifying novel modulators of the GnRH pathway. Its predictable antagonistic activity and resistance to rapid degradation make it an attractive reference compound for screening and validating new chemical entities targeting the GnRH receptor. Furthermore, its application in preclinical models aids in the evaluation of candidate molecules for efficacy and specificity, streamlining the optimization of lead compounds. By providing a reliable benchmark for comparison, D-Pro9-Cetrorelix accelerates the development of innovative therapeutics aimed at hormonal regulation.
Cellular Pathway Analysis: D-Pro9-Cetrorelix is instrumental in studies designed to unravel the intricacies of intracellular signaling cascades initiated by GnRH receptor engagement. Researchers leverage its ability to selectively block receptor activation, thereby isolating the direct effects of GnRH antagonism on downstream effectors such as second messengers, kinases, and transcription factors. This targeted approach facilitates the identification of novel signaling nodes and regulatory checkpoints, enhancing our comprehension of receptor-mediated cellular responses. Insights gained from these studies inform the broader fields of signal transduction and receptor pharmacology.
Comparative Peptide Research: Investigators often utilize D-Pro9-Cetrorelix in comparative analyses with other GnRH analogues to delineate structure-activity relationships and optimize peptide design. By systematically evaluating its binding affinity, receptor selectivity, and metabolic stability relative to alternative compounds, researchers can refine the development of next-generation antagonists with improved pharmacological properties. Such comparative studies are essential for advancing peptide engineering and expanding the repertoire of research tools available for hormonal regulation studies.
In summary, D-Pro9-Cetrorelix stands out as a versatile and robust peptide antagonist with applications spanning reproductive biology research, endocrine signaling studies, pharmaceutical development, cellular pathway analysis, and comparative peptide research. Its unique structural modifications, coupled with its consistent biological activity, render it indispensable for scientists seeking to unravel the complexities of GnRH-mediated processes and to drive innovation in peptide-based research and development.
1. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More